Intravenous immunoglobulin in minimal change nephrotic syndrome: a crossover trial

Peter Rowe, Robert H. McLean, Edward J. Ruley, Jose R. Salcedo, Rosemary A. Baumgardner, Barbara Zaugg, E. David Mellits, Catherine DeAngelis

Research output: Contribution to journalArticle

Abstract

To determine whether intravenous immunoglobulin (IVGG) would be an efficacious adjunct in the treatment of childhood minimal change nephrotic syndrome (MCNS), we enrolled ten patients with frequently relapsing or steroid-dependent MCNS in a double-blind crossover clinical trial. At the time of relapse of the nephrotic syndrome, patients were assigned to treatment with a single outpatient infusion of IVGG (800 mg/kg) or intravenous albumin as a control. The relapse was treated concurrently with standard doses of oral prednisone. At the time of the next relapse, patients who had first received IVGG were treated with albumin, and vice versa. There were no significant differences in the length of remission between the IVGG and albumin treatments. The study had a power of 0.72 to detect a true difference of 45 days between the two therapies. We conclude that in the dose of drug used in this trial, administered at the time of relapse in conjunction with prednisone therapy to children with frequently relapsing or steroid-dependent MCNS, IVGG does not lead to a clinically important extension of the period of remission.

Original languageEnglish (US)
Pages (from-to)32-35
Number of pages4
JournalPediatric Nephrology
Volume4
Issue number1
DOIs
StatePublished - Jan 1990

Fingerprint

Lipoid Nephrosis
Intravenous Immunoglobulins
Cross-Over Studies
Recurrence
Albumins
Prednisone
Steroids
Therapeutics
Nephrotic Syndrome
Outpatients
Clinical Trials
Pharmaceutical Preparations

Keywords

  • Albumin
  • Immunoglobulin
  • Minimal change nephrotic syndrome
  • Prednisone

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Nephrology

Cite this

Rowe, P., McLean, R. H., Ruley, E. J., Salcedo, J. R., Baumgardner, R. A., Zaugg, B., ... DeAngelis, C. (1990). Intravenous immunoglobulin in minimal change nephrotic syndrome: a crossover trial. Pediatric Nephrology, 4(1), 32-35. https://doi.org/10.1007/BF00858434

Intravenous immunoglobulin in minimal change nephrotic syndrome : a crossover trial. / Rowe, Peter; McLean, Robert H.; Ruley, Edward J.; Salcedo, Jose R.; Baumgardner, Rosemary A.; Zaugg, Barbara; Mellits, E. David; DeAngelis, Catherine.

In: Pediatric Nephrology, Vol. 4, No. 1, 01.1990, p. 32-35.

Research output: Contribution to journalArticle

Rowe, P, McLean, RH, Ruley, EJ, Salcedo, JR, Baumgardner, RA, Zaugg, B, Mellits, ED & DeAngelis, C 1990, 'Intravenous immunoglobulin in minimal change nephrotic syndrome: a crossover trial', Pediatric Nephrology, vol. 4, no. 1, pp. 32-35. https://doi.org/10.1007/BF00858434
Rowe, Peter ; McLean, Robert H. ; Ruley, Edward J. ; Salcedo, Jose R. ; Baumgardner, Rosemary A. ; Zaugg, Barbara ; Mellits, E. David ; DeAngelis, Catherine. / Intravenous immunoglobulin in minimal change nephrotic syndrome : a crossover trial. In: Pediatric Nephrology. 1990 ; Vol. 4, No. 1. pp. 32-35.
@article{3e5cc8c3d33d4fc4b2668a45bf818dd1,
title = "Intravenous immunoglobulin in minimal change nephrotic syndrome: a crossover trial",
abstract = "To determine whether intravenous immunoglobulin (IVGG) would be an efficacious adjunct in the treatment of childhood minimal change nephrotic syndrome (MCNS), we enrolled ten patients with frequently relapsing or steroid-dependent MCNS in a double-blind crossover clinical trial. At the time of relapse of the nephrotic syndrome, patients were assigned to treatment with a single outpatient infusion of IVGG (800 mg/kg) or intravenous albumin as a control. The relapse was treated concurrently with standard doses of oral prednisone. At the time of the next relapse, patients who had first received IVGG were treated with albumin, and vice versa. There were no significant differences in the length of remission between the IVGG and albumin treatments. The study had a power of 0.72 to detect a true difference of 45 days between the two therapies. We conclude that in the dose of drug used in this trial, administered at the time of relapse in conjunction with prednisone therapy to children with frequently relapsing or steroid-dependent MCNS, IVGG does not lead to a clinically important extension of the period of remission.",
keywords = "Albumin, Immunoglobulin, Minimal change nephrotic syndrome, Prednisone",
author = "Peter Rowe and McLean, {Robert H.} and Ruley, {Edward J.} and Salcedo, {Jose R.} and Baumgardner, {Rosemary A.} and Barbara Zaugg and Mellits, {E. David} and Catherine DeAngelis",
year = "1990",
month = "1",
doi = "10.1007/BF00858434",
language = "English (US)",
volume = "4",
pages = "32--35",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Intravenous immunoglobulin in minimal change nephrotic syndrome

T2 - a crossover trial

AU - Rowe, Peter

AU - McLean, Robert H.

AU - Ruley, Edward J.

AU - Salcedo, Jose R.

AU - Baumgardner, Rosemary A.

AU - Zaugg, Barbara

AU - Mellits, E. David

AU - DeAngelis, Catherine

PY - 1990/1

Y1 - 1990/1

N2 - To determine whether intravenous immunoglobulin (IVGG) would be an efficacious adjunct in the treatment of childhood minimal change nephrotic syndrome (MCNS), we enrolled ten patients with frequently relapsing or steroid-dependent MCNS in a double-blind crossover clinical trial. At the time of relapse of the nephrotic syndrome, patients were assigned to treatment with a single outpatient infusion of IVGG (800 mg/kg) or intravenous albumin as a control. The relapse was treated concurrently with standard doses of oral prednisone. At the time of the next relapse, patients who had first received IVGG were treated with albumin, and vice versa. There were no significant differences in the length of remission between the IVGG and albumin treatments. The study had a power of 0.72 to detect a true difference of 45 days between the two therapies. We conclude that in the dose of drug used in this trial, administered at the time of relapse in conjunction with prednisone therapy to children with frequently relapsing or steroid-dependent MCNS, IVGG does not lead to a clinically important extension of the period of remission.

AB - To determine whether intravenous immunoglobulin (IVGG) would be an efficacious adjunct in the treatment of childhood minimal change nephrotic syndrome (MCNS), we enrolled ten patients with frequently relapsing or steroid-dependent MCNS in a double-blind crossover clinical trial. At the time of relapse of the nephrotic syndrome, patients were assigned to treatment with a single outpatient infusion of IVGG (800 mg/kg) or intravenous albumin as a control. The relapse was treated concurrently with standard doses of oral prednisone. At the time of the next relapse, patients who had first received IVGG were treated with albumin, and vice versa. There were no significant differences in the length of remission between the IVGG and albumin treatments. The study had a power of 0.72 to detect a true difference of 45 days between the two therapies. We conclude that in the dose of drug used in this trial, administered at the time of relapse in conjunction with prednisone therapy to children with frequently relapsing or steroid-dependent MCNS, IVGG does not lead to a clinically important extension of the period of remission.

KW - Albumin

KW - Immunoglobulin

KW - Minimal change nephrotic syndrome

KW - Prednisone

UR - http://www.scopus.com/inward/record.url?scp=0025181754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025181754&partnerID=8YFLogxK

U2 - 10.1007/BF00858434

DO - 10.1007/BF00858434

M3 - Article

C2 - 2206878

AN - SCOPUS:0025181754

VL - 4

SP - 32

EP - 35

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 1

ER -